Robeco Institutional Asset Management B.V. Sells 2,239 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Robeco Institutional Asset Management B.V. cut its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 22.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,761 shares of the medical research company’s stock after selling 2,239 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Bio-Rad Laboratories were worth $2,550,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Blue Trust Inc. lifted its stake in Bio-Rad Laboratories by 7.2% during the fourth quarter. Blue Trust Inc. now owns 1,132 shares of the medical research company’s stock worth $379,000 after purchasing an additional 76 shares during the last quarter. SG Americas Securities LLC grew its holdings in Bio-Rad Laboratories by 156.7% during the 4th quarter. SG Americas Securities LLC now owns 3,221 shares of the medical research company’s stock worth $1,058,000 after acquiring an additional 1,966 shares during the period. Ballentine Partners LLC grew its holdings in Bio-Rad Laboratories by 5.2% during the 4th quarter. Ballentine Partners LLC now owns 714 shares of the medical research company’s stock worth $235,000 after acquiring an additional 35 shares during the period. UMB Bank n.a. grew its holdings in Bio-Rad Laboratories by 41.6% during the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock worth $36,000 after acquiring an additional 32 shares during the period. Finally, Polianta Ltd grew its stake in shares of Bio-Rad Laboratories by 21.2% in the 4th quarter. Polianta Ltd now owns 4,000 shares of the medical research company’s stock valued at $1,314,000 after buying an additional 700 shares during the period. 65.24% of the stock is currently owned by institutional investors.

Bio-Rad Laboratories Trading Down 2.1 %

Shares of BIO stock opened at $353.34 on Tuesday. The company’s fifty day simple moving average is $340.61 and its two-hundred day simple moving average is $335.68. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.14 and a quick ratio of 4.52. Bio-Rad Laboratories, Inc. has a 1 year low of $262.12 and a 1 year high of $387.99. The stock has a market capitalization of $9.89 billion, a price-to-earnings ratio of -12.93 and a beta of 0.90.

Analyst Upgrades and Downgrades

Several analysts have recently commented on BIO shares. Citigroup raised their target price on Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Royal Bank of Canada restated an “outperform” rating and issued a $481.00 target price on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Finally, StockNews.com upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, November 1st. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Bio-Rad Laboratories presently has an average rating of “Moderate Buy” and an average target price of $394.20.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.